Characterization of the gait in patients with RRMS and SPMS measured by FeetMe[®]: Results of the MS Feet PRO study

M. Otano Martínez²⁷, E. Moral Torres²⁸, R. Arroyo González²⁹, J. Fenández³⁰, R. Romero Sevilla³⁰, G. Izquierdo Ayuso³¹

¹Hospital la Fe, Valencia, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Álvaro Cunqueiro, Vigo, Spain, ⁴Hospital clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ⁷Hospital Arnau Vilanova, Lleida, Spain, ⁸L'Hospital Santa Catarina de Salt, Girona, Spain, ⁹Hospital Miguel Servet, Zaragoza, Spain, ¹⁰Hospital General Albacete, Albacete, Spain, ¹⁴Complejo Hospitalario Universitario de Cáceres, Spain, ¹⁵Hospital Regional Universitario de Málaga, Spain, ¹⁸Hospital Reus, ¹⁸Hospital Reus, ¹⁹Hospital Ramón y Cajal, Madrid, Spain, ²⁰Hospital San Cecilio, Granada, Spain, ²¹Hospital Reus, Reus, Spain, ²²Hospital Universitario Cabueñes, Gijón, Spain, ²³CEMCAT, Hospital de Bellvitge, Barcelona, Spain, ²⁶H Reina Sofía, Córdoba, Spain, ²⁷Complejo Hospitalario de Navarra, Navarra, Spain, ²⁸Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²⁹Quirón Salud, Madrid, Spain, ³⁰Novartis Pharmaceuticals, Barcelona, Spain, ³¹Hospital Vithas, Sevilla, Spain.

Introduction

- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that causes severe physical limitations and lack of autonomy.
- Gait disorder causes disability and decreases quality of life in MS patients. For this reason, gait analysis contributes significantly to monitor disease progression.
- FeetMe[®] was the first validated medical device allowing a portable monitoring of the gait of MS patients which objectively assesses and monitors gait disorder in MS patients.

Objective

• The aim of the present study was to characterize gait pattern in relapsing-remitting MS (RRMS) and secondary-progressive MS (SPMS) patients (objective criteria) measured by FeetMe[®] and collected with the 2-minute walk test (2MWT).

Methods

- MsFeet PRO (CBAF312AES03) is an observational, non-interventional, cross-sectional and multicenter study carried out at a national level with patients diagnosed with MS recruited consecutively by neurologists, 30 public and private hospitals in Spain.
- Inclusion criteria: patients 18-65 years old, diagnosed with MS (McDonald 2010/2017 criteria), with EDSS between 2.5-6.5, and relapse free within 30 days from recovery prior to the study initiation.
- Patients were classified as SPMS or RRMS according to two perspectives: - Objective criteria: RRMS according to McDonald 2010/2017 criteria, and SPMS according to physicians' criteria plus patients with RRMS who met Lorscheider et al (2016) criteria.
- Subjective criteria: according to physicians' criteria.
- All patients performed three tests with FeetMe[®] device:
- **2MWT**: which measured the distance (meters) a patient could walk quickly on a flat surface for two minutes with or without resting. The 2MWT was derived from the 6MWT, selecting the first 120 seconds after the beginning of the 6MWT
- 6-minute walk test (6MWT): which measured the distance (meters) a patient could walk quickly on a flat surface for six minutes with or without resting.
- Timed 25-foot walk test (T25FWT): measured the time (seconds) needed to walk 25 feet, as fast as possible and safely.
- Primary endpoint was the gait pattern measured by FeetMe[®] and collected in the 2MWT.
- Main gait parameters analyzed were:
- Distance obtained in 6MWT (meters).
- Distance obtained in 2MWT (meters)
- Velocity (cm/s): obtained as the ratio between walked distance and ambulation time.
- Cadence (steps/min): number of steps taken in one minute.
- Ambulation time (seconds): time taken to perform the test
- Stride length (cm): measured on the progression line between two consecutive heel centers of the same foot.
- Stride time (seconds): time between the initial contact instants of two consecutive steps on the same foot.
- **Double support** (gate cycle; %): the two periods when both feet were in contact with the ground are called initial double support and final double support.
- An intention-to-treat (ITT) analysis was conducted. See flowchart in Figure 1.

Figure 1. Patients included in the ITT population of the MsFeet PRO study

474 enr	olled patients		 449 evaluable patients (ITT population*) 305 RRMS (67.9%) 144 SPMS (32.1%) 	P-val e) A RRMS SPMS Tota
 25 patients excluded due to non-compliance with the selection criteria: 1 patient withdrew informed consent before using the FeetMe[®] device 24 patient did not provide data for the 2MWT, 6MWT or 25FWT 			P-val g) S RRMS SPMS	

*ITT population included all patients enrolled in the study who fulfilled all selection criteria in which any of the gait parameters had been obtained using FeetMe® device (2MWT, 6MWT or T25FWT). Patients who withdrew informed consent were not included in this population. 2MWT, 2-minute walk test; 6MWT, 6-minute walk test; ITT, intention-to-treat; T25FWT, timed 25-foot walk test

Charact Age, yea Sex, fer Educati Basi Prim Seco Highe Current Activ

Non-EDSS s

Mear Medi

Years s

Years s Years s[;]

Presen

EDSS, Expanded Disability Status Scale; ITT, intention to treat; MS, multiple sclerosis; n, number of patients; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; SPMS, secondary-progressive multiple sclerosis

P-vale for difference between RRMS and SPMS patients <0.0001

B. Casanova Estruch¹, C. Oreja Guevara², E. Álvarez Rodríguez³, M.R. Blasco Quílez⁴, V. Meca Lallana⁵, J.E. Meca Lallana⁶, L. Brieva Ruiz⁷, R. Robles⁸, J.R. Ara Callizo⁹, E. Fernández Díaz¹⁰, M.Á. Hernández Pérez¹¹, J. Dotor García-Soto¹², I. Lopez Dequidt¹³, M. Gómez Gutiérrez¹⁴, A. Alonso Torres¹⁵, M.L. Martínez Ginés¹⁶, L. Querol Gutiérrez¹⁷, E. Munteis²⁴, N. Sola Valls²¹, R. Suárez Moro²², X. Montalban²³, M. Mendibe Bilbao²⁴, S. Martínez Yelamos²⁵, E. Agüera Morales²⁶,

Results

Baseline sociodemographic and clinical characteristics

305 patients with RRMS (67.9% of the total ITT population) and 144 patients with SPMS (32.1%) were included (Table 1)

Table 1. Sociodemographic and clinical characteristics of patients included in the analysis (ITT population)


	······································				
cteristic	RRMS (N=305)	SPMS (N=144)	Total (N=449)		
years, mean (SD)	46.5 (8.7)	52.2 (7.4)	48.3 (8.7)		
emale, n (%)	205 (67.2%)	82 (56.9%)	287 (63.9%)		
ation level, n (%)					
sic education	1 (0.3%)	0 (0.0%)	1 (0.2%)		
mary education	45 (14.9%)	32 (22.5%)	77 (17.3%)		
condary education	106 (35.0%)	50 (35.2%)	156 (35.1%)		
pher education	151 (49.8%)	60 (42.3%)	211 (47.4%)		
nt employment status, n (%)					
tive	136 (44.6%)	29 (20.3%)	165 (36.8%)		
n-active	169 (55.4%)	114 (79.7%)	283 (63.2%)		
score					
an (SD)	3.6 (1.1)	5.3 (1.1)	4.2 (1.3)		
dian	3.5	5.5	4.0		
since first symptoms, mean (SD)	15.8 (8.8)	20.4 (8.5)	17.3 (8.9)		
since MS diagnosis, mean (SD)	13.4 (8.4)	18.0 (8.3)	14.9 (8.6)		
since MS progression, mean (SD)	-	4.5 (4.6)	4.5 (4.6)		
nce of ≥1 relapses in the last year, n (%)	53 (17.4%)	5 (3.5%)	58 (12.9%)		

Gait parameters obtained in the 2MWT measured by FeetMe[®]


• Figure 2 shows the main gait parameters assessed in the 2MWT, comparing between RRMS and SPMS patients (objective criteria).

Figure 2. Gait parameters comparison between RRMS and SPMS patients in the 2MWT (ITT population)

a) Step count (number of steps):



b) Distance (m):



The coloured bars represent, for each parameter, the mean value. Standard deviation is shown inside the brackets. The thinner black bars represent the minimum and maximum values registered.


Cm, centimetre; GC, gate cycle; m, meter; RRMS, relapsing-remitting multiple sclerosis; s, second; SPMS, secondary progressive multiple sclerosis.

Other results collected with FeetMe[®] in 6MWT and T25FWT

• 6-minute walk test:

(p<0.0001) (**Figure 3**).

Figure 3. Performance (distance in meters) on the 6MWT for RRMS and SPMS patients



The coloured bars represent the mean distance walked in meters. Standard deviation shown inside brackets. The thinner black bars represent the minimum and maximum distance walked in meters. M, meter; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.

• Timed 25-foot walk test:

Figure 4. Performance (time in seconds) on the T25FW for RRMS and SPSMS patients



Conclusions

- in 2MWT

Disclosures

BC have received compensations form Merck, Sanofi-Genzyme, Biogen-Idec, Novartis, and Roche to participate in advisory board. COG has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva. EAR has received speaker and consultation fees from Merck, Almirall, Bayer Hispania, Biogen and Sanofi-Aventis. VML has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche, Terumo, Sanofi, Teva, Celgene and BMS. JEML has received grants and consulting or speaking fees from Almirall, Biogen, Bristol-Meyers-Squibb, Genzyme, Merck, Novartis, Roche and Teva. LB has received honoraria, travel expenses, speaker fees and advisory fees from Bayer, Celgene, Biogen, Genzyme, Merck, Novartis, Roche, Almirall and Teva. RRC has received compensation for consulting services and speaking honoraria from Biogen Idec, Novartis, Bayer, Merck-Serono, Genzyme, Teva Pharmaceutical Industries Ltd, Almirall, and Roche. JRA has received consulting honoraria from Biogen Idec and Novartis, and honoraria for lecturing, travel expenses for attending meetings, or financial support for research from Bayer, Biogen Idec, Merck Serono, Sanofi and Novartis. **MAHP** has received speaker and consulting fees from Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Merck Serono, Novartis Sanofi-Aventis, Roche Pharma, Teva Pharmaceuticals. JDGS has received consulting, research grant support, or speaker honoraria from Merck, Sanofi-Genzyme, Allergan, Biogen, Roche, UCB and Novartis. ILD has received honoraria from Novartis and Sanofi. MGG has received speaker honoraria from Novartis, Biogen, Merck Serono, Genzyme, Bristol-Myers, Bial. AAT has received speaker honoraria from Biogen, Novartis, Roche, Merck, Genzyme and Almirall. MLMG has received compensation for consulting services and speaking fees from Merck, Biogen, Novartis, Sanofi-Genzyme, Almirall, Bayer, BMS, ROCHE and TEVA. LQG has received research grants from Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain), GBS-CIDP Foundation International, Novartis Pharma Spain, Roche, UCB and Grifols; provided expert testimony to Grifols, CSL Behring, Novartis, Sanofi-Genzyme, Merck, Annexon, Johnson and Johnson, Alexion, UCB, Takeda and Roche; serves at Clinical Trial Steering Committee for Sanofi Genzyme and is Principal Investigator for UCB's CIDP01 trial. EM has received speaker honoraria from Novartis. Merck, Biogen, Sanofi, Roche. LCFF has received speaker and consulting honoraria from Almirall, Bayer, Biogen, Biopas, Celgene, Ipsen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. RPM has received speaker honoraria from Almirall, Biogen, Merck, Novartis, Roche and Sanofi-Aventis. **NSV** has received speaking honoraria from Genzyme-Sanofi, Merck-Serono, Almirall and travel reimbursement from Genzyme-Sanofi and Roche for international and national meetings over the last 3 years. RSM has received speaker honoraria from Biogen, Roche, Sanofi and Merck. XM has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with AbbVie, Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS. **SMY** received honoraria compensation to participate in advisory boards, collaborations as a consultant and scientific communications and received research support, funding for travel and congress expenses from Roche, Biogen Idec, Novartis, TEVA, Merck, Gencyme, Sanofi, Bayer, Almirall and Celgene. EAM has received consulting fees from Novartis, BMS, Merck, Roche, Biogen. EMT has received honoraria as consultant in advisory boards, and or as chairperson or lecturer in meetings, and has also participated in clinical trials and other research projects promoted by Actelion, Almirall, Bayer, Biogen-Idec, Bristol Myers Squibb, Merck-Serono, Teva, Novartis Roche and Sanofi-Genzyme. **JF** is an employee of Novartis Pharmaceuticals. RRS is an employee of Novartis Pharmaceuticals. GIA has received Advisory Board honoraria and research projects from Novartis, Sanofi, Merck Serono, Roche, Actelion, Celgene and Teva. MBQ, EFD, MMB, MOM and RAG have nothing to disclose.

Acknowledgements

- Mean (standard deviation) 6MWT score: 356.7 (103.1) meters for RRMS patients and 255.8 (106.0) for SPMS patients

- Mean (standard deviation) time to complete T25FW: 7.0 (3.7) seconds for RRMS patients and 12.4 (24.1) for SPMS patients (p=0.0002) (Figure 4).

-	- 7.0s (3.7)	10 4- (04 4)					
	8.6s (13.9)	12.4s (24.1) ———					
5s	10s	15s	20s	25s	30s	35s	40s

The coloured bars represent the mean time to complete the test in seconds. Standard deviation shown inside brackets. The thinner black bars represent the minimum and maximum time to complete the test in seconds.

RRMS, relapsing-remitting multiple sclerosis; s, second; SPMS, secondary progressive multiple sclerosis

• SPMS patients walked a significantly shorter distance at a lower speed, cadence, and stride length than RRMS patients

In addition, SPMS patients showed a significant increase in stride time and double support gait cycle than RRMS patients Overall, SPMS patients performed worse than RRMS patients in 2MWT, 6MWT and T25FWT measured by FeetMe[®]. • FeetMe® is a medical device able to objectively characterize the gait of RRMS and SPMS patients in real time This characterization could detect punctual and progressive worsening in the gait pattern. It might also serve to indirectly detect progression through observing gait pattern deterioration in real time.

We thank IQVIA and Carmen Barrull and Marco Pinel for providing medical editorial assistance with this poster. This study was financed by Novartis Pharmaceuticals

Poster presented at the 8th Congress of the European Academy of Neurology – 25-28 June 2022, Vienna